IU neurodegenerative disorders expert shares her journey toward developing better Alzheimer’s treatments
As director of the IU Center for Neurodegenerative Disorders, Donna Wilcock leads one of the nation’s largest treatment and clinical trial sites for Alzheimer’s disease.
Cerebrovascular expert brings background in stroke and Alzheimer’s disease research to the IU School of Medicine
Candice Brown joined the IU School of Medicine to grow the school’s neurovascular basic science and clinical research programs.
From folding proteins to unfolding memories: An AI journey through Alzheimer's
This is the final column in a four-part series from Taeho Jo, assistant professor of radiology and imaging sciences at the IU School of Medicine,
Neuroscience experts collaborate to advance minimally invasive procedure to treat movement disorders
Stereotactic and functional neurosurgery specialists in the Department of Neurological Surgery and movement disorder specialists in the Department of Neurology have been performing the deep
Two IU leaders in Alzheimer's disease research receive international acclaim
IU Alzheimer's disease researchers Bruce Lamb and Donna Wilcock received prestigious awards at the Alzheimer’s Association International Conference, recognizing them as leaders and mentors in
End of an era: Neurological Surgery education director retires after 43 years of service
After more than four decades with IU School of Medicine, beloved Education Director Mary Gallagher will be saying farewell to the Department of Neurological Surgery.
AI in Medicine: What is your 'aha' moment?
This column is the third in a four-part series from Taeho Jo, titled "AI in Medicine: From Nobel Discoveries to Clinical Frontiers."
The Protein Folding Problem: The day AI unlocked a secret of life
This column is the second in a four-part series from Taeho Jo, titled "AI in Medicine: From Nobel Discoveries to Clinical Frontiers."
IU neurologist's research leads to first FDA-approved drug to treat neurofibromatosis type 1
Patients who participated in the clinical trial of the new therapy not only experienced reduction in NF1 and plexiform neurofibromas tumor volume, but also reported
AI Innovation Through the Lens of the 2024 Nobel Prizes
This column is the first in a 4-part series from Taeho Jo, PhD. titled "AI in Medicine: From Nobel Discoveries to Clinical Frontiers".